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MARKETING 
AUTHORIZATION  
• Every country has its basic legislation concerning medicinal product for human use. 
The marketing authorisation of the product is granted by the competent health 
authority. The marketing authorisation of the respective drug is granted and renewed 
on the basis of the favorable risk-benefit balance which has to maintain throughout 
the entire life cycle of the medicinal product. The life cycle of the medicinal product 
can be described as: 
•  Development, corresponding to the pre-submission phase 
•  Marketing (includes Marketing routine production)  
• Discontinuation of marketing, which may correspond to the expiration of the 
marketing authorization 
• European Union (EU) is a hub of political and economic union of 28 member states 
(MS) and extensive amount of effort was spent by the EU Commission, the EU 
parliament, the EMEA and the national authorities in updating the EU regulatory 
environment for pharmaceuticals and granting marketing authorizations within the 
EU. The primary objective of European Regulation is to safeguard public health, 
encouraging the development of the pharmaceutical industry of the European Union 
(EU) 
• Prior to marketing a medicinal product in EU a marketing authorization (MA) 
(product license) must be obtained. The company is responsible (more specifically 
“Marketing Authorisation Holder”) for placing the medicinal product on the market. 
A major and important step was taken in 1995 for the evaluation of medicinal 
products by forming the European Medicines Evaluation Agency, EMEA and the 
establishment of a centralized procedure, leading to a single EU wide evaluation and 
approval of new medicines 
PROCEDURES AND APPLICATIONS FOR MARKETING AUTHORIZATION 
OF MEDICINAL PRODUCTS 
 In general there are 4 types of marketing authorization for the drug product to enter 
into European Union drug market.  
A) Initial Marketing Authorization:  
1. CENTRALISED PROCEDURE  
2. MUTUAL RECOGNITION PROCEDURE  
3. NATIONAL PROCEDURE  
4. DECENRALISED PROCEDURE 
• 1. CENTRALIZED PROCEDURE:  
• The 'centralized procedure' for authorizing medicinal products is laid down in 
Regulation (EC) No726/2004. The centralized procedure, which is compulsory for 
products derived from biotechnology, for orphan medicinal products and for 
medicinal products for human use which contain an active substance authorized in the 
Community after 20 May 2004 (date of entry into force of Regulation (EC) No 
726/2004) and which are intended for the treatment of AIDS, cancer, 
neurodegenerative disorders or diabetes. The procedure is also compulsory for the 
products which are used as performance enhancers or to increase yields from animals  
• I) PRE-SUBMISSION: 
• a draft summary of product characteristics;  
• Eligibility  
• Strength 
•  Type of application  
• Statement of intention to request for accelerated assessment  
• Statement of whether Orphan designation is valid or pending 
• Proposed invented name 
• Request for total or partial fee exemptions 
• When an applicant decides to apply to the EMA for the drug product authorization 
then at least seven months before the submission of application, the applicant should 
notify the EMEA of their intention to submit an application. So, the applicant will 
have the opportunity to meet the EMA‟s product team in person in a PreSubmission 
meeting where the procedural, regulatory and legal advice will be provided to the 
applicant 
• The applicant‟s request for eligibility for evaluation via the Centralized Procedure, 
together with a justification and other documents is presented to all CHMP 
[Committee for Medicinal Products for Human Use] members. Following discussion 
at CHMP, the EMEA informs the applicant whether the product is eligible for 
evaluation via the Centralized Procedur 
• Amongst the members of CHMP a Rapporteur and a CoRapporteur will be appointed 
for the purpose of scientific evaluation and to prepare an Assessment Report for the 
CHMP on the application. This Assessment report will be submitted to the CHMP and 
EMA on DAY 80 where a peer review will be done by the members of CHMP for the 
validity of Scientific/Regulatory conclusions. A list of Questions raised by the CHMP 
along with the conclusions and review of scientific data will be sent to the applicant 
on DAY 120.At this point EMA stops the clock for giving time to applicant for 
responding to the data with proper responses. After receipt of the responses from the 
applicant, the CHMP adopts a timetable for the evaluation of the responses  
• The EMEA ensures that the opinion of the CHMP is given in 90 additional days. 
After the positive opinion of CHMP, the applicant provides the EMEA with final 
translations of the necessary documents in all EU languages and the clock resumes 
from this point. A draft decision will be prepared within fifteen days by the 
commission on the application, and then the medicinal product will be assigned by a 
Community registration number which will be placed on product‟s package if the 
authorisation is granted. Finally, within 30 days the EMEA transmits the CHMP 
opinion and other required documents to the European Commission, and the 
Members of the Standing Committee, and to Norway and Iceland. 
• The applicant may go for the other procedures like Mutual Recognition Procedure 
(MRP) or the Decentralized Procedure (DCP) if the product does not fall within the 
mandatory scopes of the Centralized Procedure (CP) 
 
 
• Mutual Recognition Procedure: The Regulation for the mutual recognition 
procedure is laid down in Directive 2001/83/EC. The mutual recognition procedure is 
mandatory for all medicinal products to be marketed in a Member State other than 
they were first authorized, since 1 January 1998. The mutual recognition procedure is 
used in order to obtain marketing authorizations in several Member States where the 
medicinal product in question has received a marketing authorization in any of the 
Member State at the time of application. 
• Procedure for Mutual Recognition Procedure (MRP): An application for this 
procedure can be sent to one or more Member States. The applications sent should be 
similar and all Member States must be informed of them. When a Member State 
decides to assess the application (atthis point it becomes the "Reference Member 
State" RMS), it announces the decision to other Member States (which then become 
the "Concerned Member States" CMS), to whom applications have also been 
submitted by the applicant. At this juncture the CMS will suspend their evaluations 
on the particular application and waits for the RMS‟s decision on the application  
• Usually the procedure ends with the marketing authorization granted by the RMS 
after the evaluation of the application. In the other case RMS can be the country 
which had already approved the product; in such a case the RMS updates the existing 
assessment report in 90 days. The updated report will be sent to all the member states 
along with the summary of product characteristics (SPC), labeling and package 
leaflet. After receiving the reports from RMS, the Concerned Member States will 
have 90 days to recognize the decision made by the RMS on the report and the other 
documents. Upon the positive decision, a national marketing authorization will be 
granted in each of the CMS(s) 
3. NATIONAL PROCEDURE:  
• The national procedure is like the other procedures but in this case only one member 
state is involved. The documents submitted to an authority are very specific to that 
particular authority and evaluation of the application is carried out by the same 
member state. The evaluation time for an application for a national marketing 
authorization is 210 days from the receipt of the application. But this procedure is 
stringently limited from 1 January 1998 to the early phase of mutual recognition 
(granting of the marketing authorization by the Reference Member State) and to 
medicinal products which are not to be authorized in more than one Member State.  
• 4. DECENTRALIZED PROCEDURE:  
• The new Decentralized procedure came into effect in the European Union in 2005 
and is regulated by Directive 2004/27/EC. The main purpose of this procedure is to 
acquire marketing authorizations in several Member States, even though there are no 
marketing authorization has been granted in the European area.  
• Steps involved in Decentralized procedure (DCP): The applicant has to send an 
application to the respective authorities of each and every member States, where there 
is plan to attain a marketing authorization. Unlike MRP, here the applicant may assign 
a country to act as the Reference Member State. This selection can be based on many 
criteria like workload, previous experience, interests of the applicant and acceptance 
of the applied dossier by the RMS.  
• The RMS will commence the assessment after the application is decided to be 
complete by both the RMS and all the CMS(s). The RMS then forwards a preliminary 
Assessment Report on the submitted dossier to the CMS(s) and the applicant in a 
period of 70 days. The CMS(s) is requested to give comments on the proposed 
national prescription status and to inform the RMS. On day 105, the RMS will 
forward all observation and remarks from the CMS(s) to the applicant and stops the 
clock if necessary, until the applicant prepares a response document for the comments 
sent. The RMS prepares a Draft Assessment Report on day 120 and may close the 
procedure if a consensus has been reached between the CMS(s) and the RMS. 
Otherwise the CMS(s) has 90 more days to approve the Draft Assessment Report, and 
other documents. 
• Authorities of the RMS and the CMS(s) agree to a decision within 30 days after 
acknowledgement of their agreement to the Assessment Report and other documents. 
Upon the positive agreement, a national marketing authorization will be issued in the 
RMS and each of the CMS(s) 
 
• Coordination Group for Mutual Recognition and Decentralized Procedure for Human 
Medicinal Products (CMDh): When one or more Member States cannot recognize an 
authorization already granted in an MRP or a final assessment and the product 
information prepared in a DCP, the disagreement is referred to the Coordination 
Group for Mutual Recognition and Decentralized Procedure for Human Medicinal 
Products (CMDh). Within a timeframe of 60 days, Member States shall, within the 
coordination group, make all efforts to reach a consensus. In case this fails, the 
procedure is submitted to the appropriate EMEA scientific committee (CHMP or 
CVMP, as appropriate).The opinion of the EMEA Committee is then forwarded to the 
Commission, for the start of the decision making process.  
VARIATIONS:  
• Variations are nothing but the modifications requested by the applicant after the grant 
of a marketing authorization. The submission of variation applications makes sure 
that the dossier and the Summary of Product Characteristics (SPC) are always kept up 
to date.  
• During the life cycle of a medicinal product, the modifications are repeatedly made to 
the dossier, which may be simple changes, such as a change in the manufacturing 
method or a change in a manufacturer (Type 1 variations) and also can be quite 
complex, such as the application for a new indication, where new clinical and pre-
clinical data has to be presented 
Type IA VARIATIONS (NOTIFICATIONS: “DO AND TELL”):  
• Type IA and Type IAIN: In case of Type IA variations notification shall be submitted 
within 12 months from the date of implementation and in case of Type IAIN 
variations notification shall be submitted immediately after implementation. This type 
of variations does not have serious impact on quality, safety and efficacy of product. [ 
Type IB: (“TELL, WAIT and DO”)  
• Type IB Variations are processed in an efficient and timely manner. The quality of the 
submission and supporting documentation is responsibility of Marketing 
Authorization Holder (MAH)  
• This type of variations also does not have any potential effect on the quality, safety 
and efficacy of product. But, without proper supporting documentation the case may 
be considered as Type II Variation 
MARKETING AUTHORIZATION PROCEDURES 
Type II Variations:  
• These types of variations have significant impact on quality, safety and efficacy of 
product and require prior approval before implementation.  
• The 60 and 90-day time frames for evaluation of procedure are maximum time lines 
thus allowing flexibility for shorter procedures in particular situations. In such cases 
MAH should contact to the RMS as soon as possible for proposed procedure.  
Extension of a marketing authorization:  
• A line extension is a change to a marketing authorization that cannot be classified as a 
variation. Line extension applications are examined in accordance with the procedure 
for the granting of a new marketing authorization.  
•  Examples of a line extension are: 
•   Application for a product with a new strength  
•  Application for a product with a new pharmaceutical form 
•   The dossier of the line extension can partially refer to the dossier of the initial 
product.  
The eCTD standard has advantages, which can be summarized as follows:  
 For pharmaceutical companies it facilitates changing and reuse of documents 
  Following the changes throughout the lifecycle  
 Creating links to other documents  
But eCTD is not only an “electronic CTD”, because it covers the content, meta data, and 
structure of the application within the XML backbone, spans the full product lifecycle, 
and always provides the current information in context, without having cross-reference 
and duplicate information manually, it is more definitive - no file can be modified 
without any control, it stores the version numbers of the documents. 
• Dossier Compilation: T 
• The compilation of a dossier based on the eCTD standard specified the Module 1 contain the region specific 
administrative and prescribing product information and Module 2-5 as per the ICH specifications. The ICH 
CTD specifies that Module 1 should contain region specific administrative and prescribing product 
information. Module 1 is country specific and it contains information as below:  
• 1.0 Cover letter  
• 1.1 Comprehensive table of contents,  
• 1.2 Application form, 1.3 Product information  
• 1.3.1 SPC, Labelling and Package Leaflet  
• 1.3.2 Mock-up  
• 1.3.3 Specimen  
• 1.3.5 Consultation with Target Patient Groups  
• 1.3.6 Braille  
• 1.4 Information about the experts  
• 1.4.1 Quality 1.4.2 Non-Clinical 1.4.3 Clinical  
• 1.5 Specific requirements for different Types of Applications 
•  1.5.1 Information for Bibliographical Applications  
• 1.5.2 Information for Generic, „Hybrid‟ or Biosimilar Applications 
•  1.5.3 (Extended) Data / Market Exclusivity  
• 1.5.4 Exceptional Circumstances 
•  1.5.5 Conditional Marketing Authorization  
• 1.6 Environmental Risk Assessment  
• 1.6.1 Non-GMO  
• 1.6.2 GMO 
• 1.7 Information relating to orphan market exclusivity (if required)  
• 1.7.1 Similarity  
• 1.7.2 Market Exclusivity  
• 1.8 Information relating to Pharmacovigilance 
•  1.8.1 Pharmacovigilance System 
•  1.8.2 Risk-management System  
• 1.9 Information relating to clinical trials 
•  1.10 Information relating to Pediatrics 
•  1.11 Responses to Questions  
• 1.12 Additional Data.  
• Regulatory requirement for the approval of the medicinal drug in European Union 
was found to be more rigid. 
•   EU has different types of procedure and different types of applications which will 
specify the product and time frame required for the approval of the drug which helps 
in tracking of life of the respective product.  
•  The retaining of the current marketing authorization systems, DCP together with 
scope of CP provide a great flexibility of the choice between different marketing 
authorizations and also allowed to go for the national application of medicinal 
product.  
•  To harmonies and fasten the process of medicinal product evaluation, the European 
Union adopted the eCTD format for the submission.  
